Diagnosing DMD before symptoms appear may mean better motor function later
Physicians should aim to diagnose DMD as early as possible.
News
-
-
Dyne Therapeutics receives Breakthrough Therapy designation for DYNE-251
DYNE-251, developed by Dyne Therapeutics and aimed at treating DMD, has received a Breakthrough Therapy Designation.
-
Report highlights disconnect between young patients and caregivers
A new report reveals a communication gap between young people with rare diseases and their caregivers in preparing for adulthood.
-
New study shows blocking RNA molecule could boost muscle repair in DMD
A mouse study suggests that blocking microRNA-33 may one day help reduce muscle damage in people with Duchenne muscular dystrophy
-
Precision BioSciences receives FDA Orphan Drug Designation for PBGENE-DMD
Precision BioSciences has announced that PBGENE-DMD has received FDA Orphan Drug Designation.
-
People with DMD want more inclusive sex education, study finds
People with Duchenne muscular dystrophy (DMD) and similar conditions want more inclusive sexual education that meets their unique needs.
-
Researchers expand hope for DMD while grappling with setbacks
Advances in gene and small molecule therapies offer new hope for Duchenne muscular dystrophy, but no cure currently exists.
-
FDA clears way for Sarepta to restart Elevidys shipments
Patients with DMD who can still walk will regain access to Elevidys as Sarepta resumes shipments following FDA clearance.
-
Case report examines acute respiratory distress in a teenage girl with DMD
A recent case report examines the rare case of a teenage girl with DMD that was complicated by acute respiratory distress syndrome.
-
Sarepta voluntarily pauses Elevidys shipments in the US
Sarepta Therapeutics has announced that it will voluntarily stop all shipments of the DMD therapeutic agent Elevidys.
